spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Opdivo 

 HSMN NewsFeed - 3 Jan 2023
ZielBio Appoints Alan Bash CEO as Company Advances Oncology Therapeutics
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Jun 2021
Senda Biosciences Strengthens Leadership Team with Key Management Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Sep 2020
Blueprint Medicines Strengthens Leadership with Appointment of Fouad Namouni, M.D., as President, Research & Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Jan 2019
Bristol-Myers Squibb to Acquire Celgene to Create a Premier Innovative Biopharma Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Aug 2018
Synthorx Appoints Immuno-Oncology Veteran Joseph Leveque, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2018
Infinity Pharmaceuticals Appoints Samuel Agresta, M.D., M.P.H. as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2017
Arvinas Appoints Dr. John Houston as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Mar 2017
Personal Genome Diagnostics' Expanded PlasmaSELECT(TM) 64 Is First Liquid Biopsy Pan-Cancer Profiling Panel to Include MSI Analyses for Immuno-Oncology
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 21 Feb 2017
Bristol-Myers Squibb Appoints Three New Independent Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Sep 2016
aTyr Pharma Appoints Industry Veteran in Novel Biology Biologics, David J. King, PhD, as Senior Vice President, Research
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jul 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 6 Jan 2016
NextCure, Inc., New Immuno-Oncology Firm, Announces $67 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.